GHGary Hunter

Gary Hunter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gary Hunter has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of 24‐Hour Computed Tomography Infarct Density on Functional Outcomes in Stroke: Secondary Analysis From the AcT Trial

    by Umberto Pensato, Jianhai Zhang, Kazbek Barakhanov, Koji Tanaka, Fouzi Bala, Chitapa Kaveeta, Mohammed Almekhlafi, Dar Dowlatshahi, Thalia S. Field, Aleksander Tkach, et al.

    Background: The final infarct volume has been historically considered the most critical radiological outcome in ischemic stroke. Yet, discrepancies between final infarct volume and functional outcomes occur frequently. We aim to evaluate whether 24‐hour computed tomography (CT) infarct density modifies the relationship between 24‐hour CT infarct volume and functional outcomes and is associated with outcomes in acute ischemic stroke. Methods: Data are from the AcT (Alteplase Versus Tenecteplase in AIS [Acute Ischemic Stroke] Within 4.5 Hours) trial. Patients with detected 24‐hour CT infarct and no parenchymal hematoma were included. To capture within‐lesion heterogeneity, “24‐hour CT standardized infarct density” was calculated as mean Hounsfield Unit/SD for every patient. Primary outcome was the 90‐day ordinal modified Rankin Scale score. We assessed effect modification using interaction terms and performed adjusted regression analyses. Results: Of 1577 patients, 839 (53.2%) were included (median age 75 years [interquartile range, 64–84], 414 [9.3%] female). Median infarct volume was 7.5 mL (interquartile range, 1.6–28.0), and median standardized infarct density was 4.8 standardized‐Hounsfield Units (interquartile range, 4.0–5.8). Standardized infarct density significantly modified the effect of infarct volume on modified Rankin Scale score ( P ‐interaction=0.001) and mortality ( P ‐interaction=0.014). Higher standardized infarct density (ie, less severe infarct degree) was associated with better 90‐day modified Rankin Scale score (adjusted common odds ratio [acOR], 0.87 [95% CI, 0.80–0.96] per 1‐standardized‐Hounsfield Unit increase), whereas infarct volume was not (acOR, 0.96 [95% CI, 0.90–1.01] per 5‐mL increase). Conclusions: CT infarct density modifies the effect of infarct volume on outcomes and is independently associated with better outcomes. These findings suggest that 24‐hour CT infarct volume and density may provide complementary information on the infarct burden.

  • Cerebral Amyloid Angiopathy Imaging Markers, Radiological Boston Criteria, and Thrombolysis Outcomes in Ischemic Stroke

    by Shahab Marzoughi, Ibrahim Alhabli, Nishita Singh, Fouzi Bala, William Betzner, Kaden Lam, Brian Buck, Luciana Catanese, Aleksander Tkach, Dar Dowlatshahi, et al.

    BACKGROUND: Cerebral amyloid angiopathy (CAA) is thought to increase the risk of postthrombolytic intracranial bleeding, yet CAA neuroimaging markers and magnetic resonance imaging criteria have not been systematically evaluated in large acute stroke trials. We, therefore, examined the association of radiological Boston CAA criteria and their constituent markers with hemorrhagic risks and functional outcomes after intravenous thrombolysis in the AcT trial (Alteplase Compared to Tenecteplase). METHODS: Blinded raters recorded lobar cerebral microbleeds, cortical superficial siderosis, white matter hyperintensity multispot sign, and centrum semiovale enlarged perivascular spaces, and classified possible and probable CAA according to radiological Boston criteria iterations, versions 1.0, 1.5, and 2.0. Multivariable logistic or ordinal regressions, adjusted for age, sex, baseline stroke severity, diabetes, hypertension, onset-to-needle time, thrombolytic agent, and endovascular therapy, assessed associations of these features/criteria with safety end points: symptomatic intracerebral hemorrhage (ICH), any ICH, Heidelberg hemorrhage grade, 90-day mortality, and functional outcomes (modified Rankin Scale score of 0–1 and ordinal modified Rankin Scale score shift). RESULTS: Among 1600 patients in the trial, 482 had suitable magnetic resonance imaging (mean age, 71 years; 47.1% female). Cortical superficial siderosis burden emerged as the dominant harmful marker: each increment was associated with increased risk of symptomatic ICH (adjusted odds ratio [aOR] per additional affected sulcus, 3.88 [95% CI, 2.87–5.26]), any ICH (aOR, 1.91 [95% CI, 1.22–2.98]), hemorrhage severity, 90-day mortality (aOR, 1.42 [95% CI, 1.18–1.71]), worse modified Rankin Scale scores (adjusted common odds ratio, 1.74 [95% CI, 1.58–1.91]), and lower odds of excellent functional recovery (aOR, 0.70 [95% CI, 0.64–0.77]). Fulfilling probable radiological Boston criteria, versions 1.0 and 1.5, increased odds of any ICH (aOR, 2.57 and 2.39 [95% CI, 2.05–3.23]; aOR, 2.39 [95% CI, 1.71–3.34], respectively), whereas fulfilling possible Boston criteria, version 1.5, was associated with worse modified Rankin Scale scores (adjusted common odds ratio, 2.34 [95% CI, 1.30–4.22]). Boston criteria, version 2.0, were not significantly associated with any hemorrhagic outcomes. CONCLUSIONS: In thrombolyzed patients with acute ischemic stroke, cortical superficial siderosis burden is strongly and consistently associated with higher risk of severe hemorrhage, disability, and death, making it a particularly relevant CAA marker when weighing thrombolytic risk versus benefit. Meeting radiological Boston criteria, versions 1.0 or 1.5, increases hemorrhagic risk, but meeting the latest 2.0 criteria does not.


  • Open Access

    Comparing Clinical Characteristics and Outcomes of Tenecteplase Versus Alteplase in Young Adult Patients With Stroke: A Secondary Analysis of the AcT Trial

    by Katrina Hannah D. Ignacio, Fouzi Bala, Luciana Catanese, Aleksander Tkach, Mahesh Kate, Brian Buck, Ayoola Ademola, Tolulope T. Sajobi, Thalia S. Field, Aleksandra Pikula, et al.

    BACKGROUND: With the increasing use of tenecteplase for acute ischemic stroke, it is important to determine its safety in young adults. We aimed to characterize the clinical characteristics and imaging findings of young adults (≤45 years) in the AcT trial (Intravenous Tenecteplase Compared With Alteplase for Acute Ischaemic Stroke in Canada) and to compare their safety and efficacy outcomes. METHODS: This is a secondary analysis of the AcT trial, a phase 3 pragmatic multicenter registry-linked randomized controlled trial. We describe clinical and imaging characteristics of young adults with acute ischemic stroke. Logistic regression adjusted for sex and stroke severity was performed to assess safety and efficacy outcomes between the tenecteplase and alteplase arms. RESULTS: Of the 1577 enrolled patients, 68 (4.31%) were ≤45 years. Of 53 patients with available comorbidity data, 33 (62.26%) had no comorbidities. Hypertension was the most common comorbidity (n=8, 15%), whereas cardiac pathologies were observed in a smaller proportion (n=4, 7.5%). Intracranial atherosclerosis was identified in 7 patients (10%) and carotid or vertebral artery dissection in 6 patients (9%). Safety outcomes, including mortality, intracranial hemorrhage, and serious adverse events, were similar between the tenecteplase and alteplase arms. Excellent functional outcome (modified Rankin Scale score 0–1) at 90 days was better in the tenecteplase arm (84.72% versus 45%; adjusted odds ratio, 6.55 [95% CI, 1.89–22.71]). CONCLUSIONS: The majority of young adults presenting with acute ischemic stroke did not have any traditional risk factors for stroke at presentation. Safety outcomes were similar between the tenecteplase and alteplase arms. Although functional outcomes were observed to be better in the tenecteplase arm, these findings are exploratory and should be interpreted cautiously, given the study’s limited sample size and lack of adjustment for key confounders. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03889249.

  • Open Access

    Association Between Ipsilateral Stroke and Nonstenotic (<50%) Carotid Disease: Secondary Analysis From the AcT Trial

    by Katrina Hannah D. Ignacio, Shashank Nagendra, Fouzi Bala, Ibrahim Alhabli, Chitapa Kaveeta, Koji Tanaka, Elizabeth Baguley, Therese Poulin, Kirsten Sjonnesen, MacKenzie Horn, et al.

    Background: Symptomatic nonstenotic (<50% stenosis) carotid disease in the presence of high‐risk plaque features is a potential cause of ischemic stroke. We assessed stroke risk associated with symptomatic nonstenotic carotid disease. Methods: This cross‐sectional secondary analysis of the AcT (Alteplase Compared to Tenecteplase) randomized controlled trial evaluated baseline computed tomography angiograms for degree of internal carotid artery stenosis, plaque features and the presence of intraluminal thrombi, webs, dissection, and rim sign. Stroke location was evaluated on 24‐hour follow‐up imaging. At a carotid level, mixed‐effects logistic regression models adjusted for age and sex, with patient identity as a random effect, examined associations between “concordant stroke” (ipsilateral acute stroke in the internal carotid artery territory) and symptomatic nonstenotic carotid disease. Results: Of 1577 patients enrolled, 1407 (89.2%) with interpretable imaging were included: 329 (23.4%) had no carotid disease, 869 (61.8%) had nonstenotic carotid disease, and 209 (14.9%) had stenotic (≥50%) carotid disease in either the left or right internal carotid artery. Median age was 73 years (interquartile range, 63–83), with 48% female patients. Among 2519 (89.5%) internal carotid arteries with nonstenotic disease, 689 (27.4%) concordant strokes were identified. Intraluminal thrombi, carotid webs, carotid dissections, and carotid rim sign were significantly associated with concordant stroke (adjusted odds ratio, 8.11 [95% CI, 1.60–41.08]; adjusted odds ratio, 3.58 [95% CI, 1.53–8.35]; adjusted odds ratio, 6.77 [95% CI, 1.72–26.75]; and adjusted odds ratio, 3.17 [95% CI, 1.39–7.23], respectively). Results remained unchanged after excluding patients with atrial fibrillation and lacunar infarctions. Conclusions: Features other than the degree of stenosis should be considered when evaluating patients with carotid disease.


  • Faster Thrombolysis Is Associated With Improved Cognitive Outcomes in Patients With Acute Ischemic Stroke Treated With Alteplase and Tenecteplase: A Substudy of the AcT Trial

    by Sajeevan Sujanthan, Gayathiri Rajkumar, Katie N. Dainty, Morgan Barense, Krista L. Lanctot, Adrian M. Owen, Nishita Singh, Brian H. Buck, Houman Khosravani, Shelagh B. Coutts, et al.

    BACKGROUND: Cognitive impairment after stroke is linked with poorer functional outcomes. Faster thrombolytic improves recanalization, 3-month functional recovery, and in-hospital survival. We examined whether faster treatment times from door-to-needle and symptom onset-to-needle (OTN) impacted cognition. METHODS: This study is a prespecified secondary observational cohort analysis of the AcT randomized clinical trial (Alteplase Compared to Tenecteplase; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03889249) data. Eligible participants were English-speaking individuals who independently completed the trial’s primary outcome and were recruited from 18 stroke centers within Canada. Prospective cognitive outcomes were collected at 90 to 180 days using a Telephone Montreal Cognitive Assessment (T-MoCA range, 0–22; <17 impairment). The primary aim was to assess cognitive performance and its relationship with treatment times (door-to-needle and OTN) at 90 to 180 days. Linear and logistic regression analyses were used to evaluate the relationship, adjusting for treatment allocation, age, sex, baseline National Institutes of Health Stroke Scale, education, ethnicity, and occlusion location. RESULTS: Three hundred ninety-nine (50%) of 791 eligible subjects completed the T-MoCA. The mean age was 66±13 years, 38.8% were female, and the mean T-MoCA score was 16±4. Shorter OTN times (but not door-to-needle) were associated with higher T-MoCA scores on linear regression (β, −0.009 [95% CI, −0.016 to −0.002]) and with increased odds of T-MoCA impairment for every 1-minute increase on logistic regression (odds ratio, 1.005 [95% CI, 1.001–1.009]). There was no difference between the alteplase and tenecteplase subgroups in the relationship between treatment times and cognition. Each 15-minute reduction in OTN was associated with a 7.3% reduction in the probability of impairment (score <17) on the T-MoCA. CONCLUSIONS: Faster OTN time, with either alteplase or tenecteplase, was associated with higher T-MoCA scores and reduced the likelihood of impairment at 90 days. Faster thrombolytic treatment may reduce cognitive burden after stroke.


  • Safety, Functional Disability, Healthcare Utilization, and Quality-of-Life Outcomes in Elderly Receiving Alteplase and Tenecteplase: A Secondary Analysis From the AcT Trial

    by Nishita Singh, Fouzi Bala, Ayoola Ademola, Mohammed Almekhlafi, Shelagh B. Coutts, Yan Deschaintre, Houman Khosravani, Brian H. Buck, Ramana Appireddy, Francois Moreau, et al.

    BACKGROUND: Older age has been associated with overall poorer outcomes in acute ischemic stroke. We compared (1) outcomes in various health-related domains among patients P interaction =0.22). CONCLUSIONS: Similar to alteplase, increasing age was associated with poorer functional outcomes with TNK. Rates of angiographic and bleeding outcomes were similar between patients <80 and ≥80 years. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03889249.


  • Open Access

    Intravenous thrombolysis at primary stroke centers versus comprehensive stroke centers: Analysis from the AcT trial

    by Diego Gutiérrez, Katrina Ignacio, Aleksander Tkach, Herbert Manosalva, Aravind Ganesh, MacKenzie Horn, Houman Khosravani, Jai Shankar, Fouzi Bala, Mohamed A. Tarek, et al.

    Introduction: Fast delivery of intravenous thrombolysis (IVT) and transportation to a comprehensive stroke center (CSC) is paramount in primary stroke centers (PSCs), to achieve effective reperfusion. We investigated clinical outcomes and workflow times of patients treated with IVT at PSCs. Methodology: This is a secondary analysis of the AcT trial, a multicenter, phase-3, randomized, controlled, noninferiority trial comparing tenecteplase with alteplase in patients with acute ischemic stroke within 4.5 hours of onset. We compared baseline characteristics, imaging and clinical outcomes at 90 days, and workflow times between PSCs and CSCs. Results: Of 1577 patients enrolled in the trial, 99 (6.27%) were treated at PSCs and 1,478 (93.72%) at CSCs. Both groups had similar age (median 72 [64 - 82] versus 74 [63 - 83] years), proportion of females (42.42% versus 48.24%), baseline stroke severity (median National Institute of Health Stroke Scale 9 [6 - 16] versus 10 [6 - 16.5] points) and presence of large vessel occlusion (24.24% versus 24.70%). The proportion of patients achieving excellent functional outcome at 90 days was significantly higher in PSCs compared to CSCs (mRS 0-1: 48.48% versus 35.01%, adjusted IRR, 1.42 [CI 95%, 1.04 - 1.95]), without differences in safety outcomes. Patients treated at PSCs had longer onset-to-needle (median, 139 [100 - 190] versus 128 [94 - 185] minutes, p 0.026) and door-to-needle times (median, 56.5 [42 - 70] versus 35 [27 - 47] minutes, p <0.001). In the 24 patients transferred from PSCs to CSCs, those who received tenecteplase had lower needle-to-puncture times compared to those who received alteplase (median, 35.5 [21 - 58] versus 52 [18 - 74] minutes, p <0.001). Conclusions: Despite less efficient workflows for IVT and similarities in baseline characteristics, the proportion of patients treated at PSCs who had excellent functional outcomes was higher compared to CSCs. Patients who received tenecteplase prior to CSC transfer had more efficient time metrics when compared to those who received alteplase.


  • Open Access

    Safety and Efficacy of Intravenous Thrombolysis by Infarct Type in Patients with No Visible Occlusion: A Secondary Analysis of the AcT Trial

    by A. Zohaib Siddiqi, Katrina Ignacio, Chitapa Kaveeta, Fouzi Bala, Ayoola Ademola, Aleksander Tkach, Brian H. Buck, Luciana Catanese, Gary Hunter, Dar Dowlatshahi, et al.

    Background: About 25% of patients with acute ischemic stroke have lacunar infarct on follow‐up imaging. In this secondary analysis from the AcT (Alteplase Compared With Tenecteplase) trial, we assessed if there is variation in safety or efficacy of intravenous thrombolysis by infarct type in patients with no visible occlusion. We also determined if this effect differed between tenecteplase and alteplase. Methods and Results: This is a secondary analysis from the AcT trial. Lacunar infarct was defined as single, ≤15 mm, and in regions supplied by perforating arterioles on 24‐hour imaging. Outcomes included symptomatic intracerebral hemorrhage at 24 hours, any hemorrhage on imaging, and 90‐day modified Rankin Scale score. Mixed‐effects regression models adjusted for age, sex, stroke severity, thrombolytic type, and onset‐to‐needle time were used. Of 1577 patients, 456/29.9% had no visible occlusion and interpretable follow‐up imaging (magnetic resonance imaging: 41.2%). Of these 93 (20.4%) (magnetic resonance imaging: 62.3%) had lacunar infarct, 171 (37.5%) (magnetic resonance imaging: 67.4%) had nonlacunar infarct, and 192 (42.1%) (magnetic resonance imaging: 7.3%) had no visible infarct. Four patients (2.3%) in the group with nonlacunar infarct and none in the groups with lacunar infarct and no visible infarct developed symptomatic intracerebral hemorrhage. Any intracranial hemorrhage was highest (21; 12.4%) in the group with nonlacunar infarct. There was no significant interaction between thrombolytic type and treatment outcomes. Conclusions: In the AcT trial, safety of intravenous thrombolysis was similar across all infarct types in patients with no visible occlusion but functional outcomes were worst in patients with nonlacunar infarct. Safety and functional outcomes after intravenous thrombolysis were better in the groups with lacunar infarct and no visible infarct as compared with the overall trial population.


  • Intravenous alteplase versus tenecteplase in patients with acute posterior circulation strokes: A secondary analysis from the AcT randomized controlled trial

    by Petra Cimflova, Ibrahim Alhabli, Fouzi Bala, MacKenzie Horn, Faysal Benali, Brian H Buck, Luciana Catanese, Shelagh B․ Coutts, Houman Khosravani, Ramana Appireddy, et al.


  • Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial

    by Tolulope T. Sajobi, Olayinka I. Arimoro, Ayoola Ademola, Nishita Singh, Fouzi Bala, Mohammed A. Almekhlafi, Yan Deschaintre, Shelagh B. Coutts, Sibi Thirunavukkarasu, Houman Khosravani, et al.

    BACKGROUND: Recent evidence from thrombolysis trials indicates the noninferiority of intravenous tenecteplase to intravenous alteplase with respect to good functional outcomes in patients with acute stroke. We examined whether the health-related quality of life (HRQOL) of patients with acute stroke differs by the type of thrombolysis treatment received. In addition, we examined the association between the modified Rankin Scale score 0 to 1 and HRQOL and patient-reported return to prebaseline stroke functioning at 90 days. METHODS: Data were from all patients included in the AcT trial (Alteplase Compared to Tenecteplase), a pragmatic, registry-linked randomized trial comparing tenecteplase with alteplase. HRQOL at 90-day post-randomization was assessed using the 5-item EuroQOL questionnaire (EQ5D), which consists of 5 items and a visual analog scale (VAS). EQ5D index values were estimated from the EQ5D items using the time tradeoff approach based on Canadian norms. Tobit regression and quantile regression models were used to evaluate the adjusted effect of tenecteplase versus alteplase treatment on the EQ5D index values and VAS score, respectively. The association between return to prebaseline stroke functioning and the modified Rankin Scale score 0 to 1 and HRQOL was quantified using correlation coefficient ( r ) with 95% CI. RESULTS: Of 1577 included in the intention-to-treat analysis patients, 1503 (95.3%) had complete data on the EQ5D. Of this, 769 (51.2%) were administered tenecteplase and 717 (47.7%) were female. The mean EQ5D VAS score and EQ5D index values were not significantly higher for those who received intravenous tenecteplase compared with those who received intravenous alteplase ( P =0.10). Older age ( P P P =0.004) were associated with lower EQ5D index and VAS scores. There was a strong association ( r , 0.85 [95% CI, 0.81–0.89]) between patient-reported return to prebaseline functioning and modified Rankin Scale score 0 to 1 Similarly, there was a moderate association between return to prebaseline functioning and EQ5D index ( r , 0.45 [95% CI, 0.40–0.49]) and EQ5D VAS scores ( r , 0.42 [95% CI, 0.37–0.46]). CONCLUSIONS: Although there is no differential effect of thrombolysis type on patient-reported global HRQOL and EQ 5D-5L index values in patients with acute stroke, sex- and age-related differences in HRQOL were noted in this study. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03889249.